Celcuity Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Celcuity Inc. (Nasdaq: CELC) on June 30, 2025. The filing serves as a Regulation FD disclosure and reports on other events regarding the announcement of clinical data from two early-phase studies of the company's investigational drug, gedatolisib.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and does not contain financial statements or updated financial metrics.
Material Changes and Clinical Data
The primary material event is the release of preliminary Phase 1 data for gedatolisib in combination with darolutamide (Nubeqa) for patients with metastatic castration-resistant prostate cancer (mCRPC). Key findings include:
- Study Design: 38 patients were randomized to receive darolutamide plus either 120 mg or 180 mg of gedatolisib.
- Efficacy: The six-month radiographic progression-free survival rate was 66% across combined arms.
- Safety and Tolerability:
- No patients discontinued treatment due to treatment-related adverse events.
- No dose reductions were required for either drug.
- No Grade 3 hyperglycemia was reported.
- Grade 2-3 stomatitis occurred in four patients (10.5%), comprising three Grade 2 and one Grade 3 case.
Outlook, Guidance, and Risks
Future Trial Plans: The company plans to complete the Phase 1 portion with up to six patients per arm across three dose levels. Following this, up to 40 patients will be assigned to Phase 1b cohorts to determine the recommended Phase 2 dose (RP2D). A Phase 2 dose expansion study will enroll up to 18 additional subjects to reach a total of approximately 30 subjects treated with the RP2D.
Forward-Looking Statements: The filing includes standard disclaimers regarding uncertainties in clinical trial timing, regulatory approval, market acceptance, and capital access. The company explicitly states it undertakes no obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical analysis of the 66% progression-free survival rate.
- Confirm the specific timeline for the presentation of additional preliminary results at the upcoming medical conference.
- Review the company's most recent Form 10-K (filed March 31, 2025) for current cash runway and liquidity status, as this 8-K does not provide financial data.
- Monitor enrollment progress for the planned Phase 1b and Phase 2 expansion cohorts.